Kevin Marks, Delphia Therapeutics CEO

Biotech vets raise $67M to de­vel­op tar­get­ed ac­ti­va­tors for can­cer

Del­phia Ther­a­peu­tics said Thurs­day that it raised $67 mil­lion to de­vel­op tar­get­ed can­cer ther­a­pies that over­ac­ti­vate dri­vers of can­cer, de­fy­ing the norm es­tab­lished by decades …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.